Acute angle closure glaucoma induced by selective serotonin reuptake inhibitor, and reversed by agomelatine

Abstract

Agomelatine, a MT1 (Melatonin) and MT2 receptor agonist and 5-HT2C (5-Hidroksitriptamin) antagonist, is an antidepressant agent used in the treatment of major depressive disorders. Intraocular pressure lowering effect of melatonin and its analogues have been demonstrated in a few experimental studies. In the present case report, we have documented the reversal of angle closure glaucoma by oral agomelatine in a patient with major depressive disorder under selective serotonine reuptake inhibitor treatment. The patient, who had previously been diagnosed with glaucoma, was also receiving antiglaucomatous treatment.

Keywords

• agomelatine
• angle closure glaucoma